Truxima® (CT-P10) was the first biosimilar version of rituximab to be approved in Europe (February 2017) and it was launched in the UK in April 2017. A briefing sheet intended to support prescribers by providing answers to commonly asked questions about the introduction of this medicine (published April 2017) is available at the link below.